Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Return on Capital Employed (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Return on Capital Employed for 9 consecutive years, with 0.25% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 34.0% to 0.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.25% through Dec 2025, down 34.0% year-over-year, with the annual reading at 0.24% for FY2025, 36.0% down from the prior year.
  • Return on Capital Employed hit 0.25% in Q4 2025 for Protagonist Therapeutics, up from 0.26% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.33% in Q1 2024 to a low of 0.66% in Q1 2023.
  • Historically, Return on Capital Employed has averaged 0.26% across 5 years, with a median of 0.28% in 2021.
  • Biggest five-year swings in Return on Capital Employed: surged 99bps in 2024 and later crashed -56bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.4% in 2021, then tumbled by -41bps to 0.56% in 2022, then skyrocketed by 48bps to 0.29% in 2023, then soared by 132bps to 0.09% in 2024, then crashed by -364bps to 0.25% in 2025.
  • Business Quant data shows Return on Capital Employed for PTGX at 0.25% in Q4 2025, 0.26% in Q3 2025, and 0.25% in Q2 2025.